MCID: PRM014
MIFTS: 28

Periampullary Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Periampullary Adenocarcinoma

Aliases & Descriptions for Periampullary Adenocarcinoma:

Name: Periampullary Adenocarcinoma 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8110
NCIt 47 C27322
UMLS 69 C1335377

Summaries for Periampullary Adenocarcinoma

MalaCards based summary : Periampullary Adenocarcinoma is related to adenocarcinoma and pancreatitis, and has symptoms including abdominal pain An important gene associated with Periampullary Adenocarcinoma is PIGR (Polymeric Immunoglobulin Receptor), and among its related pathways/superpathways are Pyrimidine metabolism and Retinoblastoma (RB) in Cancer. The drugs Ethanol and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and pancreas.

Related Diseases for Periampullary Adenocarcinoma

Diseases related to Periampullary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
id Related Disease Score Top Affiliating Genes
1 adenocarcinoma 10.6
2 pancreatitis 10.3
3 hemophagocytic lymphohistiocytosis 10.0 CDKN1B DCK
4 neurofibromatosis, type 1 9.9
5 neurofibromatosis 9.9
6 pancreatic cancer 9.7
7 somatostatinoma 9.7
8 paraganglioma 9.7
9 endotheliitis 9.7
10 basal cell carcinoma 7 9.6 CDKN1B DCK SLC29A1
11 thymus sarcomatoid carcinoma 9.2 CDKN1B DCK PIGR SATB2 SLC29A1

Graphical network of the top 20 diseases related to Periampullary Adenocarcinoma:



Diseases related to Periampullary Adenocarcinoma

Symptoms & Phenotypes for Periampullary Adenocarcinoma

UMLS symptoms related to Periampullary Adenocarcinoma:


abdominal pain

Drugs & Therapeutics for Periampullary Adenocarcinoma

Drugs for Periampullary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 3 64-17-5 702
2 Anti-Infective Agents Phase 3,Phase 2,Phase 1
3 Anti-Infective Agents, Local Phase 3
4 Central Nervous System Depressants Phase 3
5
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
6
Pancrelipase Approved Phase 2,Phase 1,Early Phase 1 53608-75-6
7
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
8
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
9
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
10
Fluorouracil Approved Phase 2 51-21-8 3385
11
Levoleucovorin Approved Phase 2 68538-85-2
12
leucovorin Approved, Nutraceutical Phase 2 58-05-9 54575, 6560146 143
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
14
Cediranib Investigational Phase 2 288383-20-0 9933475
15
Maleic acid Experimental Phase 2 110-16-7 444266
16 pancreatin Phase 2,Phase 1,Early Phase 1
17
s 1 (combination) Phase 2
18 Antimetabolites Phase 2,Phase 1
19 Antimetabolites, Antineoplastic Phase 2,Phase 1
20 Immunosuppressive Agents Phase 2,Phase 1
21 Antiviral Agents Phase 2,Phase 1
22
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
23 Protein Kinase Inhibitors Phase 2,Phase 1
24 Liver Extracts Phase 2,Phase 1
25 Trace Elements Phase 2
26 Vitamin B Complex Phase 2
27 Vitamins Phase 2
28 Protective Agents Phase 2
29 Antidotes Phase 2
30 Micronutrients Phase 2
31 Calcium, Dietary Phase 2
32 Folate Nutraceutical Phase 2
33 Vitamin B9 Nutraceutical Phase 2
34
Capecitabine Approved, Investigational Phase 1 154361-50-9 60953
35
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
36
motexafin gadolinium Investigational Phase 1 156436-89-4 12047567
37 Dermatologic Agents Phase 1
38 Histone Deacetylase Inhibitors Phase 1
39 Photosensitizing Agents Phase 1
40
Secretin Approved, Investigational Early Phase 1 108153-74-8
41
Menthol Approved Early Phase 1 2216-51-5 16666
42
Cefotaxime Approved 63527-52-6 456256 5742673
43
Cefoxitin Approved 35607-66-0 441199
44
Vitamin A Approved, Nutraceutical, Vet_approved Early Phase 1 11103-57-4, 68-26-8 445354
45 Gastrointestinal Agents Early Phase 1
46 Hormone Antagonists Early Phase 1
47 Hormones Early Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Early Phase 1
49 Chelating Agents
50 Retinol palmitate Early Phase 1

Interventional clinical trials:

(show all 32)
id Name Status NCT ID Phase
1 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
2 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
3 Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer Completed NCT00806611 Phase 3
4 Effect of Probiotics in Patients Undergoing Surgery for Periampullary Neoplasms Completed NCT01468779 Phase 3
5 SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer Unknown status NCT01811277 Phase 2
6 Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma Recruiting NCT01781728 Phase 2
7 Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Terminated NCT00832637 Phase 2
8 Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Terminated NCT01229111 Phase 2
9 Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer Withdrawn NCT00487851 Phase 2
10 Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer Completed NCT00983268 Phase 1
11 Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery Completed NCT00003798 Phase 1
12 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Recruiting NCT01825603 Phase 1
13 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Active, not recruiting NCT00987766 Phase 1
14 Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy Unknown status NCT01913275
15 Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity Unknown status NCT01371240 Early Phase 1
16 Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer Completed NCT02900950
17 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276
18 Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy Completed NCT00841607
19 Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Completed NCT02081131
20 Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage Completed NCT01789502
21 Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer Completed NCT00409864
22 Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma Completed NCT00495924
23 Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer Recruiting NCT02787512
24 Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region Recruiting NCT02780648 Early Phase 1
25 Impact of Additional DJ (Duodenojejunostomy)-Pexy on Reduction in Delayed Gastric Emptying Following Pylorus-preserving Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial Recruiting NCT02635399
26 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615
27 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02757859
28 EUS BD vs ERCP TP for Pancreatic Cancer Recruiting NCT03063554
29 T-EUS for Gastrointestinal Disorders: A Multicenter Registry Recruiting NCT01522573
30 Fatigue and Pancreas and Bile Duct Cancer Study Active, not recruiting NCT00902759 Early Phase 1
31 Comparing Three Dimension Laparoscopic Versus Open Pancreaticoduodenectomy Not yet recruiting NCT03138213
32 Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient Not yet recruiting NCT02958059

Search NIH Clinical Center for Periampullary Adenocarcinoma

Genetic Tests for Periampullary Adenocarcinoma

Anatomical Context for Periampullary Adenocarcinoma

MalaCards organs/tissues related to Periampullary Adenocarcinoma:

39
Endothelial, Liver, Pancreas

Publications for Periampullary Adenocarcinoma

Articles related to Periampullary Adenocarcinoma:

(show top 50) (show all 52)
id Title Authors Year
1
The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. ( 27275582 )
2016
2
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma. ( 27488532 )
2016
3
Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. ( 27070783 )
2016
4
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma. ( 26590090 )
2016
5
Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma. ( 26515733 )
2015
6
Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. ( 26362587 )
2015
7
Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. ( 26028992 )
2015
8
A prospective, randomized, double-blind, placebo controlled trial on the efficacy of ethanol celiac plexus neurolysis in patients with operable pancreatic and periampullary adenocarcinoma. ( 25667135 )
2015
9
Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. ( 26361410 )
2015
10
Management of periampullary adenocarcinoma by pancreaticoduodenectomy at a regional teaching hospital. ( 26261725 )
2015
11
Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. ( 25323550 )
2014
12
Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. ( 25397670 )
2014
13
Use of a standardized diagnostic approach improves the prognostic information of histopathologic factors in pancreatic and periampullary adenocarcinoma. ( 24731283 )
2014
14
Mixed periampullary adenocarcinoma and somatostatinoma with small bowel gastrointestinal stromal tumour in neurofibromatosis type 1. ( 25435578 )
2014
15
A case of periampullary adenocarcinoma in neurofibromatosis type 1. ( 25436139 )
2014
16
Ampullary and periampullary adenocarcinoma: new challenges in management of recurrence. ( 23474562 )
2013
17
FAP related periampullary adenocarcinoma. ( 23792481 )
2013
18
Large retroperitoneal paraganglioma concurrent with periampullary adenocarcinoma. ( 24523807 )
2013
19
Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. ( 23601033 )
2013
20
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. ( 22782416 )
2012
21
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma. ( 22551547 )
2012
22
Adjuvant chemotherapy for resected periampullary adenocarcinoma. ( 23149995 )
2012
23
Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: perineural growth more important prognostic factor than tumor localization. ( 18580212 )
2008
24
Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. ( 18547417 )
2008
25
Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. ( 17336242 )
2007
26
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. ( 17084719 )
2006
27
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. ( 16332474 )
2005
28
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma. ( 15978737 )
2005
29
Cyclin D1 and bax influence the prognosis after pancreatoduodenectomy for periampullary adenocarcinoma. ( 15532837 )
2004
30
Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma. ( 15011922 )
2004
31
Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. ( 15531230 )
2004
32
Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. ( 12559179 )
2003
33
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. ( 12192322 )
2002
34
Survival after pancreaticoduodenectomy for periampullary adenocarcinoma: an update. ( 11520088 )
2001
35
Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. ( 11677994 )
2001
36
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( 11072167 )
2000
37
The Johns Hopkins experience with pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. ( 10939866 )
2000
38
Prospective study of gastric outlet obstruction in unresectable periampullary adenocarcinoma. ( 10594205 )
2000
39
Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. ( 10359359 )
1999
40
Periampullary adenocarcinoma: analysis of 5-year survivors. ( 10561100 )
1999
41
Implications of histological grade of tumour for the prognosis of radically resected periampullary adenocarcinoma. ( 10533763 )
1999
42
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. ( 10421536 )
1999
43
Periampullary adenocarcinoma: analysis of 5-year survivors. ( 9637545 )
1998
44
Primary nonampullary/periampullary adenocarcinoma of the duodenum. ( 9843337 )
1998
45
A study of forty-nine consecutive Whipple resections for periampullary adenocarcinoma. ( 9240943 )
1997
46
Improved results for resection of periampullary adenocarcinoma. ( 9184871 )
1996
47
Clinical behavior and prognostic factors of periampullary adenocarcinoma. ( 7487210 )
1995
48
Mixed cellular population in primary and metastatic periampullary adenocarcinoma of the duodenum: report of a case. ( 7633200 )
1994
49
Pancreaticoduodenectomy for periampullary adenocarcinoma. ( 7952456 )
1994
50
Cytogenetic characterization of a periampullary adenocarcinoma of the pancreas, its liver metastasis, and a cell line established from the metastasis and a cell line established from the metastasis in a patient with Gardner's syndrome. ( 8076346 )
1994

Variations for Periampullary Adenocarcinoma

Expression for Periampullary Adenocarcinoma

Search GEO for disease gene expression data for Periampullary Adenocarcinoma.

Pathways for Periampullary Adenocarcinoma

GO Terms for Periampullary Adenocarcinoma

Biological processes related to Periampullary Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleobase-containing compound metabolic process GO:0006139 8.62 DCK SLC29A1

Sources for Periampullary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....